DRDC

Revive Therapeutics Provides Corporate Update

Retrieved on: 
Tuesday, March 12, 2024
DRDC, Neuroprotection, Tremor, Diazepam, Chronic pain, COVID, Soman, National security, Survival, NAC, Seizure, Partnership, Nervous system, VX, COVID-19, Nerve agent, Patient, Brain, Heart rate, Research, Diarrhea, Endocytosis, RVV, Death, Doctor of Philosophy, Health Canada, Trial of the century, Cough, Traumatic brain injury, CDC, Harvard University, Fever, Sarin, Bleeding, Safety, Chemical warfare, Saliva, Therapy, Disorder, Blurred vision, FDA, Economics, Nerve, Hospital, Pharmaceutical industry

TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product.

Key Points: 
  • TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product.
  • Exposure to nerve agents can cause tightness of the chest, excessive salivation, abdominal cramps, diarrhea, blurred vision, tremors, and death.
  • In addition, Revive may evaluate the potential of its proposed long COVID diagnostic product as a companion to Bucillamine.
  • The Company, under its wholly-owned subsidiary Revive Diagnostics Inc., is advancing the product development of a potential blood biomarker diagnostic that characterizes long COVID.

Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada

Retrieved on: 
Tuesday, January 16, 2024
Organ transplantation, RVV, Research, Nerve, Seizure, Survival, University, NAC, Injury, Inflammation, Neuroprotection, DRDC, Diazepam, Public, Infection, National security, Disorder, FDA, Therapy, Bleeding, Brain, Health Canada, Endocytosis, Pharmaceutical industry

TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced an update on the Company’s project evaluating Bucillamine as a potential treatment for nerve agent exposure with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence.

Key Points: 
  • TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced an update on the Company’s project evaluating Bucillamine as a potential treatment for nerve agent exposure with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence.
  • The Company and the DRDC have finalized the research protocol and expect the project to be completed by the end of Q2-2024.
  • DRDC is investigating pharmacological compounds that can mitigate nerve agent induced brain injury.
  • Bucillamine and NAC will be evaluated to determine the effect on GABA(A) receptor endocytosis and the effect on diazepam effectiveness in terminating seizures.

Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure

Retrieved on: 
Tuesday, October 17, 2023
Infection, Attack, Bleeding, Health Canada, Therapy, Brain, NAC, RVV, CSE, National security, Diazepam, Disorder, DRDC, Nerve, Seizure, Canada, Research, Pharmaceutical industry, Revive

TORONTO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced that it has entered into an agreement with Defence R&D Canada - Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence, to evaluate Bucillamine as a potential treatment for nerve agent exposure.

Key Points: 
  • TORONTO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced that it has entered into an agreement with Defence R&D Canada - Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence, to evaluate Bucillamine as a potential treatment for nerve agent exposure.
  • The DRDC will fund the research project, which is expected to begin in early Q1-2024.
  • DRDC is investigating pharmacological compounds that can mitigate nerve agent induced brain injury.
  • “We are excited to work with the DRDC in evaluating Bucillamine as a potential therapeutic for nerve agent exposure and validating the novel uses and formulations of Bucillamine for public health medical emergencies, including pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks,” said Michael Frank, CEO of Revive.

Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development

Retrieved on: 
Wednesday, October 11, 2023
Infection, ASPR, Inflammation, Injury, Development, Office of Inspector General, U.S. Department of Health and Human Services, Defence Research and Development Canada, University, Organization, Therapy, Administration, Organ transplantation, FDA, Biomedical Advanced Research and Development Authority, RVV, CSE, Acute respiratory distress syndrome, Disorder, DRDC, BARDA, Administration for Strategic Preparedness and Response, HHS, Research, Pharmaceutical industry, Bucillamine

TORONTO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, provides an update on the development of a next generation lyophilized formulation of Bucillamine.

Key Points: 
  • TORONTO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, provides an update on the development of a next generation lyophilized formulation of Bucillamine.
  • Under an agreement with the University of Waterloo, formulation development is ongoing and aims to be completed by the end of December 2023.
  • The Company expects to have its novel lyophilized formulation of Bucillamine ready for clinical evaluation in 2024.
  • The Company intends to explore the novel Bucillamine formulation as a potential treatment for public health medical emergencies including, pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks.

Immervision Awarded $5.7 Million Contract from DRDC to Develop Panoramic Imaging Systems

Retrieved on: 
Tuesday, September 5, 2023
Hardware, Other Defense, Contracts, Security, Consumer Electronics, Technology, Audio, Video, Defense, Trucking, General Automotive, Transport, Automotive, Public Transport, Internet, Mobile, Wireless, Internet of things, Defence Research and Development Canada, Partnership, DRDC, Television

Immervision , the world’s leading developer of advanced vision systems combining optics, image processing, and sensor fusion technology, is pleased to announce the award of a $5.7 million contract from Defence Research and Development Canada (DRDC) for the design and development of panoramic imaging components and systems.

Key Points: 
  • Immervision , the world’s leading developer of advanced vision systems combining optics, image processing, and sensor fusion technology, is pleased to announce the award of a $5.7 million contract from Defence Research and Development Canada (DRDC) for the design and development of panoramic imaging components and systems.
  • This contract underscores Immervision’s industry leading expertise and commitment to creating solutions to see beyond human vision that offer an extended field of view in all environments, vital for situational awareness and operational effectiveness.
  • “Our technology offers wide-angle vision systems featuring Smart Pixel Management, which holds significant potential across diverse applications,” explains Alessandro Gasparini, Executive Vice President and Chief Commercial Officer of Immervision.
  • The unparalleled quality provided by Immervisions panoramic imaging technology, components and systems have had a profound impact globally in products innovation and the development of new solutions for complex imaging challenges.

Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development

Retrieved on: 
Tuesday, August 22, 2023
ASPR, Defence Research and Development Canada, Cell biology, CSE, University, Biomedical Advanced Research and Development Authority, Therapy, Biochemistry, Doctor of Philosophy, HHS, U.S. Department of Defense Strategy for Operating in Cyberspace, Public, Office of Inspector General, U.S. Department of Health and Human Services, University of Saskatchewan academics, Injury, Research, Infection, Postgraduate education, Central Department of Chemistry, Tribhuvan University, Disorder, DRDC, Assistant, Inflammation, RVV, Development, Graduate, Administration, Organ transplantation, Administration for Strategic Preparedness and Response, Acute respiratory distress syndrome, FDA, BARDA, Dean (education), Pharmaceutical industry, Science, Bucillamine

In addition, the Company may explore the use of the novel Bucillamine formulation as a potent antioxidant and anti-inflammatory treatment for orphan indications in rare inflammatory disorders such as ischemia-reperfusion injury resulting from solid organ transplantation.

Key Points: 
  • In addition, the Company may explore the use of the novel Bucillamine formulation as a potent antioxidant and anti-inflammatory treatment for orphan indications in rare inflammatory disorders such as ischemia-reperfusion injury resulting from solid organ transplantation.
  • The Company has entered into a sponsored research agreement with the University of Waterloo to develop a novel lyophilized Bucillamine injectable formulation for public health medical emergencies and rare inflammatory disorders.
  • Upon completion of the formulation development, which is expected by end-2023, the Company will seek to initiate research studies in line with the Company’s commitment to advancing the clinical and commercial development of Bucillamine through the following strategic initiatives:
    Target Indications: Novel Bucillamine in an injectable version to expand on its potential therapeutic utility targeting rare disorders such as ischemia-reperfusion injury (i.e.
  • At this time, the Company will only provide regular updates via press releases as information becomes available.

Cellula successfully completes demonstration missions using hydrogen fuel cell powered AUV

Retrieved on: 
Monday, August 15, 2022
ADSA, Multimedia, Science and technology, Industry, Science, DRDC, TAS, Royal Australian Navy, Future of the Royal Australian Navy, Research, Defence Science and Technology Group, Royal Canadian Navy, Seawolf, Australian Defence Force, RAN, View, S&T, AUV, Arm, University, WIN, Robotics, Australia–United States Free Trade Agreement, Human, Autonomous system, Program, Vancouver-Fraserview, Jet fuel, BC, Technology

BURNABY, BC, Aug. 15, 2022 /PRNewswire/ - Cellula Robotics Ltd. is excited to announce the successful completion of various demonstration missions using the hydrogen fuel cell powered autonomous underwater vehicle (AUV), Solus-LR.

Key Points: 
  • BURNABY, BC, Aug. 15, 2022 /PRNewswire/ - Cellula Robotics Ltd. is excited to announce the successful completion of various demonstration missions using the hydrogen fuel cell powered autonomous underwater vehicle (AUV), Solus-LR.
  • The operation was the first of its kind and demonstrated near real-time, over-the-horizon communications from a submerged AUV.
  • Built on a research and development project originally sponsored by DRDC under the All Domain Situational Awareness (ADSA) Science and Technology (S&T) Program that developed Solus-LR, the mission re-enforced the capabilities and potential of a long-range, hydrogen fuel cell powered AUV designed for submerged missions in excess of 2,000 km.
  • Cellula Robotics continue to impress on the SeaWolf program, along with the contributions of our many Australian partners in the consortium.

Center for Identification Technology Research Celebrates 20th Year

Retrieved on: 
Thursday, June 30, 2022
Department, Aware, Inc., Qualcomm, Security, Buffalo Museum of Science, Federal Bureau of Investigation, Ageing, WVU, DRDC, IDEMIA, Research, University, S&T, GLOBE, San Jose State University, National Science Foundation, National, University at Buffalo, Defence Research and Development Canada, Industry, Buffalo, CCDC, Idiap Research Institute, Office of Biometric Identity Management, SICPA, Faculty, State bureau of investigation, Bias, Defense, DHS Science and Technology Directorate, Security agency, Michigan State University, Privacy, Clarkson University, Government, Clarkson, National Security Agency, Center, Algorithm, Citer, Management, Security printing, Private investigator, Science, West Virginia University

Potsdam, NY, June 30, 2022 (GLOBE NEWSWIRE) -- The Center for Identification Technology Research (CITeR), based at Clarkson University, is celebrating its 20th year.

Key Points: 
  • Potsdam, NY, June 30, 2022 (GLOBE NEWSWIRE) -- The Center for Identification Technology Research (CITeR), based at Clarkson University, is celebrating its 20th year.
  • CITeR, which performs research in the growing areas of identity science and biometric recognition, is a National Science Foundation Industry-University Cooperative Research Center.
  • Since awarding its first research grants in 2002, CITeR has performed cutting-edge research as new problems evolve each year.
  • The research found that accurate identification by fingerprint in adults remained high over a 12- 15 -year period.

Patriot One Technologies Delivers Innovative Solution for Protecting First Responders and Firefighters Using Advanced AI Platform

Retrieved on: 
Monday, June 6, 2022
Woman, Defence Research and Development Canada, Program, Stroke, School, Man, Classification, Smoke, Safety, FRA, Machine learning, Phase 1, Personal protective equipment, DRDC, CEO, AI, Firefighter, Partnership, Environment, PPE, Weapon, Solution, Intelligence, GLOBE, Risk, Technology, Review, TSX, Twitter, Canada, Infarction, CAD, Heat exhaustion, Fire, ML, Medical device, Satellite navigation device

This partnership is part of Canadas Head Up Hands Free program, which is aimed at helping firefighters work safer within dangerous environments.

Key Points: 
  • This partnership is part of Canadas Head Up Hands Free program, which is aimed at helping firefighters work safer within dangerous environments.
  • This specific application of our AI platform will aid firefighters every time they venture into physically dangerous building locations to fight fires and to save trapped occupants.
  • Innovation Solutions Canada tasked us to help address this situation using insights from sensors, correlated data, computer vision and our AI platform to solve this problem.
  • Patriot One, through development by Xtract AI, its AI innovation and development arm, will provide a range of hardware and software technology solutions to achieve the goal of making firefighters jobs safer.

Cellula Robotics Ltd. partners with Trusted Autonomous Systems and the Royal Australian Navy on the SeaWolf XLUUV Project

Retrieved on: 
Thursday, May 12, 2022
Software, Engineering, RAN, Robotics, TAS, Multimedia, Business development, View, Seawolf, Bay, Royal Australian Navy, DRDC, Future of the Royal Australian Navy, ISO, Solus, 3D printing, BC

Funded by the Royal Australian Navy (RAN) and in collaboration with sovereign sub-contractors, project SeaWolf is set to debut the first 12m XLUUV hull in the fourth quarter of 2022.

Key Points: 
  • Funded by the Royal Australian Navy (RAN) and in collaboration with sovereign sub-contractors, project SeaWolf is set to debut the first 12m XLUUV hull in the fourth quarter of 2022.
  • The SeaWolf project builds on Cellula's existing Solus-LR system and uses the proven Solus control architecture and software.
  • Demonstration missions with Solus-LR and the prototype SeaWolf XLUUV will take place in the first quarter of 2023 in Australia.
  • Cellula Robotics Ltd. is a proudly Canadian, privately owned, world leading marine technology company specializing in turnkey design and production of subsea robotic systems.